{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T22:45:58Z","timestamp":1786401958236,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-04161-x","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T12:39:12Z","timestamp":1767703152000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["miR-146b-5p promotes prostate cancer progression by targeting and negatively regulating FOXO3 and its mechanism"],"prefix":"10.1186","volume":"24","author":[{"given":"Baoji","family":"Xing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meini","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"4161_CR1","doi-asserted-by":"crossref","unstructured":"Chakroborty D, Singh AP. Prostate cancer: insights into disease progression and therapeutic challenges. Int J Mol Sci. 2024;25(5):2451.","DOI":"10.3390\/ijms25052451"},{"key":"4161_CR2","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"4161_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.575261","volume":"10","author":"S Yu","year":"2020","unstructured":"Yu S, Hong G, Tao J, Shen Y, Liu J, Dong B, et al. Multivariable models incorporating multiparametric magnetic resonance imaging efficiently predict results of prostate biopsy and reduce unnecessary biopsy. Front Oncol. 2020;10:575261.","journal-title":"Front Oncol"},{"key":"4161_CR4","doi-asserted-by":"publisher","first-page":"1516544","DOI":"10.3389\/fpsyg.2025.1516544","volume":"16","author":"H Zhang","year":"2025","unstructured":"Zhang H, Liu Z, Ye Y, Long X, Yu T, Zhang Y, Dai Z, Du J, Chen L. Experience of sexual relationship of patients after radical prostatectomy: a qualitative study. Front Psychol. 2025;16:1516544.","journal-title":"Front Psychol"},{"key":"4161_CR5","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13578-023-00985-w","volume":"13","author":"YH Chen","year":"2023","unstructured":"Chen YH, Chen H, Lin TT, Zhu JM, Chen JY, Dong RN, Chen SH, Lin F, Ke ZB, Huang JB, et al. ARPC1A correlates with poor prognosis in prostate cancer and is up-regulated by glutamine metabolism to promote tumor cell migration, invasion and cytoskeletal changes. Cell Biosci. 2023;13:38.","journal-title":"Cell Biosci"},{"key":"4161_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.ebiom.2016.09.017","volume":"12","author":"MY Shah","year":"2016","unstructured":"Shah MY, Ferrajoli A, Sood AK, Lopez-Berestein G, Calin GA. MicroRNA therapeutics in cancer - an emerging concept. EBioMedicine. 2016;12:34\u201342.","journal-title":"EBioMedicine"},{"key":"4161_CR7","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1373\/clinchem.2015.242800","volume":"62","author":"F Matin","year":"2016","unstructured":"Matin F, Jeet V, Clements JA, Yousef GM, Batra J. MicroRNA theranostics in prostate cancer precision medicine. Clin Chem. 2016;62:1318\u201333.","journal-title":"Clin Chem"},{"key":"4161_CR8","doi-asserted-by":"crossref","unstructured":"Moya L, Meijer J, Schubert S, Matin F, Batra J. Assessment of miR-98-5p, miR-152-3p, miR-326 and miR-4289 expression as biomarker for prostate cancer diagnosis. Int J Mol Sci. 2019;20(5):1154.","DOI":"10.3390\/ijms20051154"},{"key":"4161_CR9","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.3892\/ol.2015.3645","volume":"10","author":"K Duan","year":"2015","unstructured":"Duan K, Ge YC, Zhang XP, Wu SY, Feng JS, Chen SL, Zhang LI, Yuan ZH, Fu CH. miR-34a inhibits cell proliferation in prostate cancer by downregulation of SIRT1 expression. Oncol Lett. 2015;10:3223\u20137.","journal-title":"Oncol Lett"},{"key":"4161_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.apjtm.2016.09.011","volume":"10","author":"Y Yang","year":"2017","unstructured":"Yang Y, Guo JX, Shao ZQ. miR-21 targets and inhibits tumor suppressor gene PTEN to promote prostate cancer cell proliferation and invasion: an experimental study. Asian Pac J Trop Med. 2017;10:87\u201391.","journal-title":"Asian Pac J Trop Med"},{"key":"4161_CR11","doi-asserted-by":"crossref","unstructured":"Testa U, Pelosi E, Castelli G, Labbaye C. miR-146 and miR-155: two key modulators of immune response and tumor development. Noncoding RNA. 2017;3(3):22.","DOI":"10.3390\/ncrna3030022"},{"key":"4161_CR12","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s10689-017-0056-0","volume":"17","author":"X Hao","year":"2018","unstructured":"Hao X, Xia L, Qu R, Yang X, Jiang M, Zhou B. Association between miR-146a rs2910164 polymorphism and specific cancer susceptibility: an updated meta-analysis. Fam Cancer. 2018;17:459\u201368.","journal-title":"Fam Cancer"},{"key":"4161_CR13","first-page":"1136","volume":"7","author":"Y Zhu","year":"2017","unstructured":"Zhu Y, Wu G, Yan W, Zhan H, Sun P. MiR-146b-5p regulates cell growth, invasion, and metabolism by targeting PDHB in colorectal cancer. Am J Cancer Res. 2017;7:1136\u201350.","journal-title":"Am J Cancer Res"},{"key":"4161_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1159\/000369676","volume":"35","author":"X Deng","year":"2015","unstructured":"Deng X, Wu B, Xiao K, Kang J, Xie J, Zhang X, Fan Y. MiR-146b-5p promotes metastasis and induces epithelial-mesenchymal transition in thyroid cancer by targeting ZNRF3. Cell Physiol Biochem. 2015;35:71\u201382.","journal-title":"Cell Physiol Biochem"},{"key":"4161_CR15","doi-asserted-by":"publisher","first-page":"350","DOI":"10.7150\/jca.6394","volume":"4","author":"BA Walter","year":"2013","unstructured":"Walter BA, Valera VA, Pinto PA, Merino MJ. Comprehensive microrna profiling of prostate cancer. J Cancer. 2013;4:350\u20137.","journal-title":"J Cancer"},{"key":"4161_CR16","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.18632\/aging.101534","volume":"10","author":"S Gao","year":"2018","unstructured":"Gao S, Zhao Z, Wu R, Wu L, Tian X, Zhang Z. MiR-146b inhibits autophagy in prostate cancer by targeting the PTEN\/Akt\/mTOR signaling pathway. Aging. 2018;10:2113\u201321.","journal-title":"Aging"},{"key":"4161_CR17","doi-asserted-by":"publisher","first-page":"8464","DOI":"10.1002\/cam4.5587","volume":"12","author":"M Naito","year":"2023","unstructured":"Naito M, Ikeda K, Aoyama S, Kanamoto M, Akasaka Y, Kido Y, et al. Par14 interacts with the androgen receptor, augmenting both its transcriptional activity and prostate cancer proliferation. Cancer Med. 2023;12:8464\u201375.","journal-title":"Cancer Med"},{"key":"4161_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2025.1592779","volume":"16","author":"B Hua","year":"2025","unstructured":"Hua B, Yang Q, Song S, Li W, Xu B, Gu Y. Exploring the prognostic significance and therapeutic potential of SUCLG2 in prostate cancer. Front Genet. 2025;16:1592779.","journal-title":"Front Genet"},{"key":"4161_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/jmr.3042","volume":"36","author":"G Ashok","year":"2023","unstructured":"Ashok G, Das R, Anbarasu A, Ramaiah S. Comprehensive analysis on the diagnostic role of circulatory exosome-based miR-92a-3p for osteoblastic metastases in prostate adenocarcinoma. J Mol Recognit. 2023;36:e3042.","journal-title":"J Mol Recognit"},{"key":"4161_CR20","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/emmm.201100136","volume":"3","author":"AI Garcia","year":"2011","unstructured":"Garcia AI, Buisson M, Bertrand P, Rimokh R, Rouleau E, Lopez BS, Lidereau R, Mika\u00e9lian I, Mazoyer S. Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol Med. 2011;3:279\u201390.","journal-title":"EMBO Mol Med"},{"key":"4161_CR21","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2022.11155","volume":"23","author":"L Shi","year":"2022","unstructured":"Shi L, Su Y, Zheng Z, Qi J, Wang W, Wang C. miR-146b-5p promotes colorectal cancer progression by targeting TRAF6. Exp Ther Med. 2022;23:231.","journal-title":"Exp Ther Med"},{"key":"4161_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2021.153448","volume":"224","author":"B Liang","year":"2021","unstructured":"Liang B, Zhou C, Cui S, Lu H, Xu R, Xue D, et al. Upregulation of miR-18a-5p promotes the proliferation of prostate cancer via inhibiting the expression of SLC40A1. Pathol Res Pract. 2021;224:153448.","journal-title":"Pathol Res Pract"},{"key":"4161_CR23","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.biopha.2015.07.015","volume":"75","author":"W Zhao","year":"2015","unstructured":"Zhao W, Cao L, Zeng S, Qin H, Men T. Upregulation of miR-556-5p promoted prostate cancer cell proliferation by suppressing PPP2R2A expression. Biomed Pharmacother. 2015;75:142\u20137.","journal-title":"Biomed Pharmacother"},{"key":"4161_CR24","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s10495-014-1071-3","volume":"20","author":"J Wang","year":"2015","unstructured":"Wang J, Liu S, Yin Y, Li M, Wang B, Yang L, Jiang Y. FOXO3-mediated up-regulation of Bim contributes to rhein-induced cancer cell apoptosis. Apoptosis. 2015;20:399\u2013409.","journal-title":"Apoptosis"},{"key":"4161_CR25","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/pros.22698","volume":"73","author":"S Shukla","year":"2013","unstructured":"Shukla S, Bhaskaran N, Maclennan GT, Gupta S. Deregulation of FoxO3a accelerates prostate cancer progression in TRAMP mice. Prostate. 2013;73:1507\u201317.","journal-title":"Prostate"},{"key":"4161_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.abb.2020.108363","volume":"687","author":"J Li","year":"2020","unstructured":"Li J, Ma W, Cheng X, Zhang X, Xie Y, Ji Z, et al. Activation of FOXO3 pathway is involved in polyphyllin I-induced apoptosis and cell cycle arrest in human bladder cancer cells. Arch Biochem Biophys. 2020;687:108363.","journal-title":"Arch Biochem Biophys"},{"key":"4161_CR27","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1093\/nar\/gkw027","volume":"44","author":"WW Du","year":"2016","unstructured":"Du WW, Yang W, Liu E, Yang Z, Dhaliwal P, Yang BB. Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2. Nucleic Acids Res. 2016;44:2846\u201358.","journal-title":"Nucleic Acids Res"},{"key":"4161_CR28","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12943-018-0856-3","volume":"17","author":"Y Liu","year":"2018","unstructured":"Liu Y, Ao X, Ding W, Ponnusamy M, Wu W, Hao X, Yu W, Wang Y, Li P, Wang J. Critical role of FOXO3a in carcinogenesis. Mol Cancer. 2018;17:104.","journal-title":"Mol Cancer"},{"key":"4161_CR29","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1158\/1078-0432.CCR-13-1687","volume":"20","author":"D Ni","year":"2014","unstructured":"Ni D, Ma X, Li HZ, Gao Y, Li XT, Zhang Y, et al. Downregulation of FOXO3a promotes tumor metastasis and is associated with metastasis-free survival of patients with clear cell renal cell carcinoma. Clin Cancer Res. 2014;20:1779\u201390.","journal-title":"Clin Cancer Res"},{"key":"4161_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101096","volume":"14","author":"L Jin","year":"2021","unstructured":"Jin L, Zhang J, Fu HQ, Zhang X, Pan YL. FOXO3a inhibits the EMT and metastasis of breast cancer by regulating TWIST-1 mediated miR-10b\/CADM2 axis. Transl Oncol. 2021;14:101096.","journal-title":"Transl Oncol"},{"key":"4161_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bcp.2019.06.010","volume":"168","author":"A Alwhaibi","year":"2019","unstructured":"Alwhaibi A, Verma A, Artham S, Adil MS, Somanath PR. Nodal pathway activation due to Akt1 suppression is a molecular switch for prostate cancer cell epithelial-to-mesenchymal transition and metastasis. Biochem Pharmacol. 2019;168:1\u201313.","journal-title":"Biochem Pharmacol"},{"key":"4161_CR32","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1158\/0008-5472.CAN-17-3512","volume":"78","author":"H Shin","year":"2018","unstructured":"Shin H, Cha HJ, Na K, Lee MJ, Cho JY, Kim CY, Kim EK, Kang CM, Kim H, Paik YK. O-GlcNAcylation of the tumor suppressor FOXO3 triggers aberrant cancer cell growth. Cancer Res. 2018;78:1214\u201324.","journal-title":"Cancer Res"},{"key":"4161_CR33","doi-asserted-by":"publisher","first-page":"15875","DOI":"10.1038\/s41598-025-00909-3","volume":"15","author":"XY Meng","year":"2025","unstructured":"Meng XY, Li Y, Yan ZJ, Ye SZ, Wang KJ, Chen JF, Yu R, Ma Q. Sinularin induces autophagy-dependent cell death by activating ULK1 and enhancing FOXO3-ATG4A axis in prostate cancer cells. Sci Rep. 2025;15:15875.","journal-title":"Sci Rep"},{"key":"4161_CR34","doi-asserted-by":"publisher","first-page":"5793","DOI":"10.12659\/MSM.904597","volume":"23","author":"XY Shi","year":"2017","unstructured":"Shi XY, Ding W, Li TQ, Zhang YX, Zhao SC. Histone deacetylase (HDAC) inhibitor, suberoylanilide hydroxamic acid (SAHA), induces apoptosis in prostate cancer cell lines via the Akt\/FOXO3a signaling pathway. Med Sci Monit. 2017;23:5793\u2013802.","journal-title":"Med Sci Monit"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-04161-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04161-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-04161-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T13:14:58Z","timestamp":1770124498000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12957-025-04161-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4161"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-04161-x","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"26 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Shandong Provincial Hospital Affiliated to Shandong First Medical University. All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"66"}}